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compliance and pressure mediated by
endothelium dysfunction; a cross-sectional study
Tomasz Zapolski1*, Andrzej Wysokiński1, Andrzej Książek2 and Andrzej Jaroszyński3Abstract
Background: This study was performed to investigate the relationship between elastic properties of aorta and left
atrium volume index (LAVI) in hemodialyzed (HD) patients.
Methods: Study group was consisted of 73 patients (age 51,6 ± 7,6 years) treated by hemodialysis. In all patients
standard echocardiography was performed. Aortic stiffness index (ASI) was calculated using formula: ASI = log (SBP/DBP)/
[(Aomax-Aomin)/Aomin]. LAVI was calculated according to the formula: LAVI = [π/6 x (LAmax x LAshort x LAlong)]/m2.
Additionally several indices were calculated: left ventricle mass (LVM), left ventricle mass index (LVMI), midwall fractional
shortening (mFS), endsystolic stress (ESS), mFS/ESS. Additionally the laboratory parameters including lipidogram, troponin
T (cTnT), NT-proBNP and asymmetric dimethylarginine (ADMA) were measured.
Results: The ASI was strong and significantly correlated with left atrium volume (LAV) and LAVI (respectively: 0,601;
p < 0,001 and 0,598; p < 0,001). The ASI was independently and markedly associated with ADMA, cTnT, CRP, T-chol,
and LDL-chol. The LAVI was independently and significantly correlated with NT-proBNP and cTnT.
Conclusions: There is correlation between ASI and ADMA, marker of endothelium dysfunction. There is also association
between LAVI and NT-proBNP, signs of elevated left atrium pressure. The strong correlation between ASI and LAVI,
improved by associations of specific biochemical markers with these echocardiographic indices, suggests there is the link
between elastic properties of aorta and left atrium pressure in hemodialysed patients mediated by endothelial
dysfunction.
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HemodialysisBackground
Cardiovascular complications are the main cause of
death in patients with end-stage renal disease (ESRD) on
renal replacement therapy [1]. Most of recent advances
in the explanation of cardiovascular complications
related to ESRD have concentrated on atherosclerosis,
and much less studies have been dedicated to evaluate
the mechanism related to hemodynamic changes oc-
curred as a consequence of renal failure and renal* Correspondence: zapolia@wp.pl
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reproduction in any medium, provided the orreplacement interventions. Morphological and functional
alterations in response to the overload of pressure and
volume characteristic for ESRD are named as uremic
cardiomyopathy.
Left atrium (LA) enlargement is a hitherto overlooked
component of the complex echocardiographic altera-
tions that are observed in ESRD. In individuals with
ESRD, left atrial volume (LAV) is independently asso-
ciated with angiographically significant coronary artery
disease, history of stroke, carotid intima-media thickness
and signs of inflammation such as high concentration of
hs-CRP [2]. Left atrium volume is adjusted to body sur-
face area and expressed as left atrium volume indexl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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potent biomarker for risk stratification and risk monitor-
ing in patients with ESRD [3].
Because the LA is exposed to left ventricle filling pres-
sures through the open mitral orifice during diastole, its
size is influenced by the same factors that determine dia-
stolic filling pressure. The diastolic dysfunction of the
left ventricle is a common finding among patients with
ESRD. One of the most important factors influencing
left ventricle function independent of blood pressure is
aortic stiffness [4].
Atherosclerosis was regarded as a combination of two
major separate diseases: atherosis and sclerosis. Sclerosis
component depends on deterioration of aortic elastic
properties and is called aortic stiffness. The stiffness of
the aorta influences aortic conduit function causes pres-
sure elevation and abnormal pressure pattern that
increases the afterload of the left ventricle. In that way
may induce left ventricle hypertrophy and alter on left
ventricle diastolic and systolic function. It is well known
that aortic stiffness is an independent predictor of all-
cause and cardiovascular mortality in different group of
patients [5] including patients who require renal replace-
ment therapy [6].
Endothelial dysfunction is a crucial precursor of the
development of cardiovascular disease. The endothelium
maintains the balance between vasoconstriction and
vasodilatation. The role of the endothelium in control-
ling the vascular tone, especially vasodilatation, has been
shown via the endothelial-derived nitric oxide (NO) [7].
Decreased NO production has also been linked to
progression of renal dysfunction [8].
Aim
This study was performed to investigate the relationship
between elastic properties of aorta and LAVI in hemo-
dialised (HD) patients. Moreover the relationship be-
tween these functional and morphological parameters
and selected biochemical markers was assessed.
Methods
Clinical characterization of studied groups
Study group was consisted of 73 patients (35 women
and 38 men in age of 51,6 ± 7,6 years) treated by
hemodialysis for mean time of 78,71(±41,04) months.
Hemodialysis were performed three times a week using
devices as: Fresenius 4008B/S (Fresenius medical care,
Bad Homburg, Germany) and Gambro AK95S (Gambro,
Lund, Sweden). Bicarbonate dialysate containing (in
millimoles per litre) 32 bicarbonate, 136–138 sodium,
2.5–4.0 potassium, 1.0 magnesium and 1.25 or 1.5 cal-
cium was used in all HD patients. The mean time of
hemodialysis session was 4.09 ± 0.11 h. The diffusive
technique was applied in all cases. During hemodialysis,no medication was applied except heparin. All patients
were hemodialysed for >6 months and were clinically
stable. Out of 73 HD patients, 46 (60,2%) were taking
angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers, 41 (56,2%) beta-blockers, 44 (60,3%)
calcium blockers and 24 (32,9%) statins.
The causes of ESRD in this group were as follow:
glomerulonephritis – 32(43,8%), diabetes mellitus – 11
(15,1%), chronic tubulo-interstitial nephritis – 3(4,1%),
obstructive nephropathy – 5(6,8%), hypertonic nephro-
pathy – 3(4,1%), polycystic kidney disease – 4(5,5%) and
unknown/uncertain – 15(20,5%).
Control group
The control group comprised of 57 volunteers (27
women and 30 men) in age of 51,9 ± 7,1 years of com-
parable to study group clinical characterization, except
that they didn’t suffer from ESRD. They have had no ab-
normalities detected by physical examination, ECG,
chest X-ray and laboratory analysis.
Echocardiography
In all patient and control subjects standard transthoracic
echocardiographic examination was performed using
2,5-3,5 MHz transducer (HP Sonos 7500, Hewlett Pack-
ard, Bloomfield, CT, USA) by the cardiologist, who was
blinded to the clinical data of the study subjects. All
echocardiographic measurements were done according
to the guidelines of the American Society of Echocardi-
ography [9]. To exclude the influence of extracellular
volume condition on systemic hemodynamic, echocar-
diographic examination was performed during first
60 minutes after a single hemodialysis session.
The following a two-dimensionally guided M-mode
echocardiographic parameters were recorded: interven-
tricular endsystolic septum diameter (IVSSd [cm]),
interventricular septum enddiastolic diameter (IVSDd
[cm]), posterior wall systolic diameter (PWSd [cm]),
posterior wall diastolic diameter (PWDd [cm]), left ven-
tricle enddiastolic diameter (LVEDd [cm]), left ventricle
endsystolic diameter (LVESd [cm]), left atrium maximal
diameter (LAmax [cm]), aortic maximal diameter
(Aomax [cm]), aortic minimal diameter (Aomin [cm]).
The dimensions of the aorta were recorded in M-mode
3 cm above the aortic valve from a parasternal long
axis view. The Aomax (systolic diameter) was measured
at the time of aortic valve maximal opening. The
Aomin (diastolic diameter) was recorded at the peak of
the QRS complex. Inner aortic diameters were mea-
sured with a caliper in systole and diastole as the dis-
tance between the trailing edge of the anterior aortic
wall and the leading edge of the posterior aortic wall
[10]. In 4-CH presentation were additionally recorded:
left atrium short diameter (LAshort [cm]), left atrium
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(LAS [cm2]) and left atrium circumference (LAC[cm]).
Consequently several standard indices were calculated
according to American Society of Echocardiography
recommendations [11] such as: left ventricle stroke
volume (SV[ml]), stroke index (SI [n]), cardiac output
(CO [l/min]), cardiac index (CI [l/min/m2]), ejection
fraction (EF [%]), fractional shortening of left ventricle
(FS [%]). Using previously measured parameters the
most important for present study indices were calculated
according to formulas:
 Left ventricle mass (LVM [g]): LVM= 1,04x[(IVSDd +
PWDd + LVEDd)3]-13,6 g
 Left ventricle mass index (LVMI [g/m2]):
LVMI = LVM/BSA
 Endsystolic stress (ESS [103dyn/cm2]): ESS =
0,334xSBPxLVESd/PWSdx(1 + PWSd/LVESd),
 Midwall fractional shortening (mFS [n]): mFS=
[(LVEDd + PWSd/2 + IVSSd/2)–(LVESd + Hs/2)/
(LVEDd + PWSD/2 + IVSSd/2)]x100; where
Hs = IVSSd + PWSd,
 Ratio mFS/ESS [n],
 Left atrium volume (LAV[ml]): LAV = LAVI=
π/6x(LAmaxxLAshortxLAlong) [12] (Figure 1),
 Left atrium volume index (LAVI [ml/m2]):
LAVI = LAV/m2
 Aortic stiffness index (ASI [n]): ASI = log
[(SBP/DBP)/(Aomax-Aomin)]/Aomin [10]
(Figure 2).
Left ventricle hypertrophy was defined by a LVMI
of > 134 g/m2 in men or > 110 g/m2 in women.
Moreover pulsed Doppler derived parameters were
measured such as: maximal velocity of early diastolicFigure 1 The measurement of diameters needed for ASI calculation.transmitral flow (E [cm/s]), maximal velocity of late dia-
stolic transmitral flow (A [cm/s]), isovolumetric relax-
ation time (IVRT [ms]), maximal systolic velocity in
pulmonary veins (S [cm/s]), maximal diastolic velocity in
pulmonary veins (D [cm/s]). Consequently ratios of E/A
and S/D were calculated. Diastolic dysfunction was
recognized accordingly to recommendation of Canadian
Cardiovascular Society [13]. Patients with restrictive
spectrum were not included to this study.
The most important for this study echocardiographic
indices were: LAVI and ASI. Patient from HD group
were divided and compared using mean values of men-
tioned indices as cut-off values.
Anthropometry, pressure and laboratory measurements
Body surface area was calculated according to formula:
BSA (m2) = 0.0235 x height(cm)0.42246 x weight(kg)0.51456
[14].
The systolic (SBP) and diastolic (DBP) pressures were
obtained using electronic sphygmomanometer (Omron
705 CP, Omron, Kyoto, Japan). The brachial artery blood
pressure measurement was made with the subjects
remaining in the left lateral decubitus position in dar-
kened, quiet room. While obtaining ascending aorta
diameters by echocardiography, blood pressure in the
right upper arm was simultaneously measured. Mean
blood pressure (MBP) was calculated by the formula:
MBP = 1/3 SBP + 2/3 DBP. Moreover the mean heart rate
calculated from the consecutive 10 beats was recorded.
The following standard parameters were measured
by automated analyzer (ADVIA Centaur analyzer,
Bayer Health-Care Diagnostics, Tarrytown, NY, USA):
hemoglobin [g/dl], sodium [mmol/l], potassium [mmol/l],
calcium [mmol/l], phosphorus [mmol/l], Ca x P score
[mg2/dl2], creatinine [μmol/l], glomerular filtration rate
Figure 2 The measurement of diameters needed for LAVI calculation.
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protein [g/l], albumin [g/l], high sensivity C-reactive pro-
tein (hs-CRP) [mg/ml], fibrinogen [g/l], total cholesterol
(T-chol) [mg/dl], HDL-cholesterol (HDL-chol) [mg/dl],
triglycerides (TGC) [mg/dl]. LDL-cholesterol (LDL-chol)
[mg/dl] was calculated using the Friedewald equation:
LDL-chol = T-chol – HDL-chol – (TGC/5). GFR was
calculated from the modification of diet in renal disease
(MDRD) formula: GFR = 186xserum creatinine-1.154 x
age-0.203 x F, where F = 1 in men and F = 0,742 in
women. Cardiac troponin T (cTnT) [(μg/l] in plasma
was measured by the electrochemiluminescence im-
munoassay (Elecsys 2010 analyser, Roche Diagnostics
Gmb, Mannheim, Germany) with the detection limit of
0,01 μg/l. NT-proBNP [fmol/ml] in plasma was measured
by the enzyme-linked immunosorbent assay - ELISA
method (Biomedica, Bratislava, Slovakia) with the detection
range between 0–640 fmol/ml. Asymmetric dimethylargi-
nine (ADMA) [μmol/l] was measured by immunoenzy-
matic method – EIA (ALPCO Diagnostics, Windham, New
Hampshire, USA) with the detection range between
0,05-3,0 μmol/l and reference range for healthy population
of 0,4-0,75 μmol/l).
The study protocol was approved by a university ethics
review board. The investigation conforms with the
principles outlined in the Declaration of Helsinki.
Reproducibility
Intraobserver variability for ASI and LAVI measure-
ments were assessed. For intraobserver variability, a
sample of 10 ASI and LAVI measurements was ran-
domly selected and examined by the same observer in
two different days after sessions of hemodialysis. Intra-
class correlation coefficients for the same observer were
calculated [15].Statistical analysis
Statistical analysis was carried out on an IBM PC using
of a standard statistical package (SPSS for Windows
Version 12.0; SPSS INC, Chicago, Illinois). Data were
expressed as mean ± SD (parametrically distributed
continuous variables) and percentage (categorical variables).
The statistical significance of the differences between HD
patients and control group means were compared by un-
paired Student’s t-test, the Mann–Whitney test, or chi-
square test with Yates correction. Pearson’s test was used
to calculate correlation coefficients. Multiple stepwise re-
gression analysis was performed to estimate the potential
influence of various laboratory, biochemical factors and
both SBP and MBP on LAVI and ASI. The following inde-
pendence parameters were entered into the model:
hemoglobin, sodium, potassium, calcium, phosphorus, Ca
x P score, creatinine, urea, total protein, albumin, hs-CRP,
T-chol, LDL-chol, HDL-chol, TGC, cTnT, NT-proBNP,




Clinical characteristics and laboratory measurements of
the study population and control group are listed in
Table 1. The heart rate and SBD, MBP were significantly
higher among HD patients compared to controls, whereas
DBP did not differ between study groups and control
group.
Baseline echocardiographic characteristic of the studied
patients and controls are shown in Table 2. All diameters
derived from a two-dimensionally guided M-mode echo-
cardiography were significantly greater either in HD
patients when compared to control group. Similarly para-
meters concerning left ventricle systolic and diastolic
Table 1 Pressure, heart rate and biochemical
measurements collected in studied patients
Parameter HD Controls p
Mean heart rate[beats/min] 74,40(±10,81) 73,47(±4,87) 0,402
Systolic blood pressure[mmHg] 139,4(±22,1) 123,7(±8,15) <0,001
Diastolic blood pressure[mmHg] 72,98(±12,02) 74,15(±9,09) 0,387
Mean blood pressure[mmHg] 95,07(±14,28) 90,60(±3,74) <0,001
Hemoglobin[g/dl] 11,98(±1,46) 13,89(±0,81) <0,001
Sodium[mmol/l] 138,5(±2,5) 138,4(±1,7) 0,583
Potassium[mmol/l] 5,698(±0,735) 4,301(±0,278) <0,001
Calcium[mmol/l] 2,259(±0,190) 2,364(±0,041) 0,007
Phosphorus[mmol/l] 1,991(±0,541) 1,09(±0,06) <0,001
Ca X P[mg2/dl2] 55,86(±14,64) 31,28(±2,65) <0,001
Creatinine [μmol/l] 777,0(±223,6) 81,33(±9,79) <0,001
Urea[mmol/l] 24,39(±7,22) 4,233(±0,897) <0,001
Total protein[g/l] 68,3(±0,52) 72,01(±0,28) <0,001
Albumin[g/l] 3,935(±0,356) 4,636(±0,204) <0,001
Hs-CRP[mg/l] 6,248(±0,23) 0,45(±0,09) <0,001
T-chol[mg/dl] 189,7(±43,75) 190,5(±22,32) 0,437
LDL-chol[mg/dl] 114,3(±30,61) 112,0(±20,43) 0,504
HDL-chol[mg/dl] 41,51(±16,19) 56,7(±11,24) <0,001
TGC[mg/dl] 170,8(±74,89) 109,1(±38,9) <0,001
cTnT[(μg/l] 0,05(±0,011) <0.01 <0,001
NT-proBNP[fmol/ml] 187,7(±96,2) 22,71(±17,23) <0,001
ADMA[μmol/l] 1,031(±0,193) 0,772(±0,253) <0,001
Table 2 Echocardiographic data
Parameter HD Controls P
Diameters of the heart
LVEDd[cm] 5,14(±0,59) 4,62(±0,44) <0,001
LVESd[cm] 3,23(±0,54) 2,91(±0,36) <0,001
PWDd[cm] 1,24(±0,24) 0,91(±0,05) <0,001
PWSd[cm] 1,60(±0,23) 1,29(±0,06) <0,001
IVSDd[cm] 1,44(±0,24) 0,94(±0,06) <0,001
IVSSd[cm] 1,67(±0,28) 1,18(±0,07) <0,001
Parameters of LV mass
LVM[g] 253,9(±92,53) 154,6(±32,6) <0,001
LVMI[g/m2] 146,5(±45,18) 97,14(±26,35) <0,001
LVH[%] 64,8 0 <0,001
Parameters of heart stroke
SV[ml] 70,39(±15,34) 79,46(±13,03) 0,009
SI [ml/beat/m2] 42,08(±11,19) 45,93(±4,22) 0,001
CO[l/min] 5,49(±0,81) 5,73(±0,49) 0,106
CI[l/min/m2] 3,24(±0,53) 3,31(±0,32) 0,126
Parameters of systolic function
EF[%] 58,91(±6,21) 65,52(±3,87) <0,001
FS[%] 31,54(±5,83) 38,9(±4,302) <0,001
mFS[%] 15,34(±3,26) 20,12(±2,87) <0,001
mFS/ESS[n] 0,186(±0,056) 0,218(±0,043) 0,002
Parameters of diastolic function
E/A[n] 0,979(±0,256) 1,371(±0,135) <0,001
IVRT[ms] 109,1(±22,73) 76,53(±14,04) <0,001
DT[ms] 229,9(±45,12) 179,3(±27,41) 0,001
S/D[n] 1,49(±0,268) 1,22(±0,181) <0,001
Relaxation abnormalities[%] 43,66 1,75 <0,001
Parameters of left atrium
LAS[cm2] 23,59(±5,1) 19,35(±3,44) <0,001
LAC[cm] 19,5(±4,58) 16,32(±3,07) <0,001
LAmax[cm] 4,3(±0,59) 3,53(±0,27) <0,001
LAV[ml] 62,52(±21,3) 36,82(±14,76) <0,001
LAVI[ml/m2] 36,29(±10,92) 20,64(±6,77) <0,001
Parameters of aorta
ASI[n] 5,51(±1,32) 3,07(±1,09) <0,001
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control group. SV and SI were decreased whereas CO and
CI did not differ between them and controls. LVM and its
index were significantly higher in HD patients. Patients
exhibited significantly greater aortic stiffness expressed by
higher value of ASI than in control group. Parameters
concerning LA were also greater in HD patients than in
control.
The current study showed a significant correlation be-
tween the ASI and LAVI (Figure 3). We have also indi-
cated a close, significant, relationship between the ASI
and the indices of left ventricular systolic function as
mFS/ESS, ESS and left ventricular diastolic function as
E/A ratio, IVRT and S/D ratio. ASI also positively corre-
lated with indicators of left ventricular hypertrophy as
follows: LVM and LVMI (Table 3).
Cut-off values of selected echocardiographic indices
After the division into subgroups using mean LAVI
value of 36,29 ml/m2, calculated for whole HD group, us
cut-off value, in subgroups of LAVI < cut-off value were
38 patients (LAVI = 33,81 ± 7,93 ml/m2) and in subgroup
of LAVI > cut-off value were 35 persons (LAVI 38,83 ±
9,37 ml/m2). Similarly study group was divided into two
subgroups due to mean calculated value ASI of 5,61 as acut-off value. The first of these subgroups of ASI < cut-
off value consisted of 37 patients with ASI 4,15 ± 1,74
and in second subgroup of ASI > cut-off value were 36
subjects with ASI 7,19 ± 1,62. The comparison of sub-
groups created by cut-off values of LAVI and ASI with
regarding to selected hemodynamic and laboratory data
are shown in Table 4.
Multiple stepwise regression analysis
The ASI had been found independently and markedly
associated with ADMA, cTnT, hs-CRP, T-chol, LDL-chol,
but not with SBP and MBP in HD patients. Multiple
Figure 3 The association between ASI and LAVI.
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LAVI was independently associated with NT-proBNP
and cTnT (Table 5).
Reproducibility
Intraclass correlation for intraobserver variability was
good for ASI measurements: 0,88; 0,77–0,95; 95% confi-
dence interval. Intraclass correlations for intraobserver
variability was also good for LAVI measurements: 0,85;
0,76–0,97; 95% confidence interval.
Discussion
LAVI and laboratory and echocardiographic parameters
Important observation of this study is that HD patients
had greater LA dimension and therefore LAV and LAVITable 3 Correlations between ASI [n] and
echocardiographic parameters
Parameter R P
LAV [ml] 0,579 p < 0,001
LAVI [ml/m2] 0,634 p < 0,001
ESV [ml] 0,336 p = 0,024
EDV [ml] 0,372 p = 0,008
LVM [g] 0,532 P = 0,001
LVMI [g/m2] 0,543 p < 0,001
E/A [n] −0,354 p = 0,009
IVRT [msec] 0,353 p = 0,021
S/D [n] −0,402 p = 0,004
ESS [%] 0,442 p = 0,002
mFS/ESS [n] −0,532 p < 0,001than control patients. These findings are important be-
cause it is well known that LAVI is an independent pre-
dictor of prognosis in HD patients providing information
to traditional clinical and Doppler echocardiographic data
[16]. We have adjusted LAV not by height, but by surface
area. The adjustment to body size using height failed to
nullify the gender influence on atrial size, unlike the ad-
justment to body surface area [17]. The diastolic dysfunc-
tion and increased LAV and LAVI in patients from
hemodialysis group may in part be attributed to an
increased LVMI as well as deteriorated elastic properties
of the aorta.
In recent years, echocardiographic assessment of the
LA and its relationship with cardiovascular risk have
been revalued. LA size, particularly LAV has been recog-
nized as a marker of diastolic dysfunction [18]. Current
guidelines in the general population jointly issued by the
American College of Cardiology, the American Heart
Association, and the European Society of Cardiology
consider the measurement of the LAV and LAVI as clin-
ically relevant information [19]. Increased LAVI is a
powerful predictor of mortality after acute myocardial
infarction and provides prognostic information incre-
mental to clinical data and conventional measure of left
ventricle systolic and diastolic function [20]. LAVI is also
useful index for prediction of adverse cardiovascular
events and may predict first ischemic stroke and subse-
quent mortality [20]. Monitoring of left atrium size by
echocardiography is also useful for predicting cardiovas-
cular risk in patients with end-stage renal disease. Chan
et al. [21] demonstrated that each mm/m2 increase in
indexed LA diameter was associated with a small but
Table 4 The comparison of calculated cut-off value of ASI
and LAVI to laboratory parameters
Parameter ASI > cut-off value
n = 36
ASI < cut-off value
n = 37
P
ADMA[μmol/l] 1,134(±0,201) 0,881(±0,169) 0,002
cTnT[μg/l] 0,068(±0,016) 0,043(±0,09) 0,001
CRP[g/l] 6,92(±0,51) 5,57(±0,21) 0,007
Total chol(mg/dl) 229,4(±46,9) 162,4(±40,2) 0,01
LDL-chol(mg/dl) 128,2(±33,5) 101,1(±27,3) 0,02
NT-proBNP[fmol/ml] 195,8(±101,5) 172,9(±92,8) 0,03
Creatinine [μmol/l] 792,0(±229,9) 762,4(±218,8) NS
Ca X P[mg2/dl2] 56,34(±15,14) 54,41(±13,81) NS
LAVI > cut-off value
n = 35
LAVI < cut-off value
n = 38
P
ADMA[μmol/l] 1,077(±0,197) 0,946(±0,159) 0,047
cTnT[μg/l] 0,063(±0,014) 0,048(±0,012) 0,001
CRP[mg/l] 6,520(±0,54) 5,905(±0,29) 0,03
Total chol[mg/dl] 201,4(±46,5) 181,2(±39,3) NS
LDL-chol[mg/dl] 119,8(±31,3) 110,1(±26,8) NS
NT-proBNP[fmol/ml] 231,2(±115,7) 136,9(±91,6) 0,001
Creatinine [μmol/l] 789,1(±231,4) 767,2(±207,4) NS
Ca X P[mg2/dl2] 57,15(±16,08) 53,11(±12,55) NS
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[21]. Changes in LAV can also predict incident cardio-
vascular events in dialysis patients independent of the
corresponding baseline measurement and of left ven-
tricular mass [3].
In the present study NT-proBNP plasma level was sig-
nificantly elevated in HD group. In literature there are
conflicting data on the influence of glomerular filtration
rate on BNP and NT-proBNP levels in ESRD. Tagore
et al. [22] suggested that unlike NT-pro BNP, plasma
BNP level is relatively independent of GFR. Most
authors suggest to use NT-proBNP when patients with
ESRD are evaluated. However data on NT-proBNP in
renal dysfunction are more concordant but were derived
from populations that included patients with impairedTable 5 Factors influencing ASI and LAVI estimated by









ASI ADMA 50,3 16,6 0,409 0,006
cTnT 121,5 34,7 0,443 < 0,001
CRP 4,92 1,83 0,281 0,002
Total chol 0,805 0,237 0,340 0,003
LDL-chol 1,427 0,428 0,329 0,004
LAVI NT-proBNP 1,16 0,453 0,328 0,007
cTnT 101,3 33,5 0,474 0,03left ventricle function or heart failure [23]. This explain
why is so difficult to account fully for the effect of coex-
istent cardiac disease, left ventricle dysfunction and vol-
ume overload, all conditions usually observed among
patients with ESRD.
Our study has revealed for the first time highly signifi-
cant correlation between LAVI and NT-proBNP among
HD patients. Association between these two parameters
was already described, but in other clinical settings. Kim
et al. [24] documented the correlation of LAVI and level
of NT-proBNP in patients with heart failure and a pre-
served ejection fraction. The combination of both LAVI
and NT-proBNP also is more useful to stratify risk of
sudden cardiac death than other clinical echocardio-
graphic or biochemical variable [25]. The combination
of these two parameters should be considered for pre-
dicting sudden cardiac deaths in patients with ESRD.
Further studies are needed to assess the possible clinical
importance of association between LAVI and NT-
proBNP in such specific group of patients.
The higher values of LAVI with coexisting elevated
plasma concentration of NT-proBNP may be a manifest-
ation of so called cardio-renal syndrome [26]. In this clin-
ical situation LA enlargement and higher NT-proBNP
levels arising from heart disease, and greater preload which
is partially caused by loss of elastic properties of aorta.
ASI and laboratory and echocardiographic parameters
We evaluated that ASI was significantly higher in
patients with ESRD than in subjects without renal dys-
function. It is well known that aortic elastic properties
are affected by the risk factors for atherosclerosis. The
coexistence of atherosclerosis and ESRD suggests there
is the link between these two diseases [27]. Atheroscler-
osis is regarded as a combination of two separate dis-
eases: atherosis and sclerosis. The aortic stiffness reflects
sclerotic component and means mechanical properties
of aortic wall. Calcium overload, which is characteristic
feature for ESRD patients, and also observed in our
patients especially before hemodialysis, is associated with
aortic stiffening. Vascular calcification is detected either
in the tunica intima or in the tunica media. Calcification
in the intima is characteristic of most stages of athero-
sclerosis. Medial calcification is particularly common in
patients with ESRD and may occur independently of ath-
erosclerosis. Medial wall calcification increases vascular
stiffness and reduces arterial compliance.
Multiple stepwise regression analysis has been shown
that the ASI is independently associated with ADMA
plasma concentration, troponin concentration, T-chol
level, LDL-chol concentration and hs-CRP in HD
patients. Our data demonstrate that HD patients have
higher levels of ADMA. The ADMA is an endogenous
competitive inhibitor of NO synthase. The ADMA
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crease with increased ADMA levels. Recently, ADMA
has been demonstrated to be a new and potentially in-
dependent marker of atherosclerosis and related cardio-
vascular disorders [28]. Endothelial dysfunction occurs
when NO activity in the vascular tissue is decreased,
resulting in decreased endothelium-dependent vasodila-
tation. ADMA is assumed to be a key regulator of NO
synthase activity, notably of the endothelial NO syn-
thase isoform. Thus, decreased NO activity might result
in vasoconstriction and in that way increase aortic stiff-
ness. To the best of our knowledge there are no data in
the literature on ADMA concentration influence on
aortic stiffness in patients with ESRD.
Accelerated vascular damage and defective vascular
repair have been proposed as a mechanism for premature
atherosclerosis and aortic stiffness, common findings
among HD patients. Impairment of NO biosynthesis
(e.g., by ADMA) or NO bioactivity (as with oxygen-
derived free radicals) causes endothelial vasodilatation
dysfunction. Thereby, the correlations between ASI
and oxygen-derived free radicals promoters such as T-
chol, LDL-chol, hs-CRP, observed in the present study,
were no surprised. The deleterious effects of T-chol,
LDL-chol and hs-CRP in part a consequence of
decreased availability of endothelium cells-derived NO,
include smooth muscle proliferation, collagen synthesis,
and deterioration of elastin which may impair arterial
compliance [29]. Taken together, our findings suggest
at least 2 pathways that could lead to increase of aortic
stiffness in HD subjects: wall calcification and endothe-
lium dysfunction.
The significant correlation was also detected between
ASI and several parameters characterizing left ventricle
function. This include correlation between ASI and
parameters characterizing systolic function as ESS and
mFS/ESS and also between ASI and diastolic parameters:
E/A ratio, IVRT and S/D ratio. We can only speculate
about the mechanism linking aortic stiffness with left
ventricle dysfunction. Loss of aortic wall compliance
causes pressure elevation and abnormal pressure pattern
that increases the afterload of the left ventricle. The re-
sult is development of left ventricle hypertrophy also
strongly associated with aortic stiffness in studied
groups.
ASI and LAVI
The most important finding of echocardiographic aspect
of the study was the significant correlation between ASI
and LAVI in patients with ESRD. In our study, we found
for the first time that HD patients with higher aortic
stiffness have greater LAVI. There are several explana-
tions for such association. Firstly, hypertension which is
a common among patients with renal failure. It is wellknown that aortic stiffness is associated with LA size in
hypertensive patients [30]. Additionally other cardiovas-
cular risk factors present in large number in HD patients
also can influence aortic stiffness and it that way stimu-
late LA enlargement [31]. All of them can modify un-
favorably of aortic intima-media structure and provoke
loss of elastic properties. In the other hand these factors
increase shear stress and stimulate endothelium dysfunc-
tion which was also proved by us by demonstrating
elevated ADMA plasma level. In result aortic compliance
became markedly deteriorated.
It is well known that increase of aortic stiffness predict
the degree of left ventricular diastolic dysfunction [32].
The main feature of this clinical state is elevation of left
ventricle diastolic pressure. Both greater values of LAVI
and high NT-proBNP plasma concentration are markers
of elevated enddiastolic pressure as well as pressure
measured in LA [33,34].
Conclusions
The results of this study suggest, that aortic elastic prop-
erties are impaired in hemodialyzed patients. The levels
of ADMA, T-chol, LDL-chol and hs-CRP may be a bio-
markers or mediators of aortic stiffness in this clinical
setting. Both LAVI and NT-proBNP concentration, signs
of elevated left atrium pressure are markedly increased
in hemodialyzed patients. The strong correlation be-
tween aortic stiffness index and LAVI, improved by asso-
ciation of specific biochemical markers with these
echocardiographic indices, suggests, that there is the link
between elastic properties of aorta and left atrium pres-
sure in hemodialysed patients mediated by endothelial
dysfunction.
Limitations of the study
The limitations of this study include its cross-sectional
nature design with relatively small number of subjects.
We do not investigate whether ASI still predict LAVI
after adjustments for other significant co-variables in-
cluding biochemical factors like NT-pro BNB, ADMA,
cTnT. Finally, aortic stiffness may be influenced by clin-
ical features that were not controlled in this study, eg.
hypertension, diabetes, smoking etc. It remains to be
determined whether these variables may alter presented
association between aortic stiffness and LAVI in hemo-
dialysed patients.
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